Monitoring To Start As EU SPC Waiver Nears Finishing Line

A manufacturing waiver to allow EU-based companies to produce generics and biosimilars during the SPC term is expected to gain final approval shortly. However, the European Commission will be watching closely to see whether the provision is actually used by industry.

Waiver
Industry's use of the EU SPC waiver will be under scrutiny • Source: Shutterstock

The European Commission is preparing to start monitoring the impact of a waiver that will allow generics and biosimilars developers to manufacture products in the EU while the originators' supplementary protection certificates (SPCs) are still in force. A plenary vote by the European Parliament in mid-April is expected to be one of the final steps in the approval of the waiver, the commission's Alfonso Calles-Sánchez told delegates at Medicines for Europe’s 15th legal affairs conference in the Dutch capital Amsterdam last week.

Noting that the inter-institutional agreement between the European Council, the European Parliament and the commission unveiled in mid-February this year...

More from Legal & IP

More from Pink Sheet

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Clinical Trial Diversity Action Plan Guidance Must Return To US FDA Website, Court Says

 
• By 

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

Industry Groups Back EU Life Sciences Strategy As Commission Pledges Clinical Trial Investment

 

Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.